Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Carboplatin + Tulmimetostat |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
Tulmimetostat | CPI0209|CPI-0209|CPI 0209 | EZH1 inhibitor 5 EZH2 inhibitor 20 | Tulmimetostat is a second-generation inhibitor of EZH1 and EZH2, which may lead to decreased tumor growth (J Clin Oncol 41, 2023 (suppl 16; abstr 3094)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05942300 | Phase I | Carboplatin + Tulmimetostat | CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer | Recruiting | USA | 0 |